FFF Enterprises: BioSupply Trends Newsletter
Monday, June 18, 2018

Study Finds No Link Between HPV Vaccine and Autoimmune Disorders Risk


In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly

There is no increased risk of autoimmune disorders in girls who receive the quadrivalent human papillomavirus (HPV4) vaccine, according to a study published in the Canadian Medical Association Journal. [ read more ]

New 10% IVIG Being Tested for Pediatric and Adult PI Patients

Evolve Biologics has dosed the first pediatric patient in its Phase III multicenter clinical trial of PlasmaCap IG (intravenous immune globulin [IVIG]), in addition to having administered half of the infusions required for the adult portion of the study, which completed enrollment in February. [ read more ]

Updated C. Diff Guidelines Reflect New Treatment Options and Recommendations

The Infectious Diseases Society of America and Society for Healthcare Epidemiology of America have updated guidelines for diagnosis and management of Clostridium difficile, which has become the leading cause of diarrhea in hospital patients and one of the most common healthcare-associated infections that sickens nearly 500,000 Americans and is associated with 15,000 to 30,000 deaths annually. [ read more ]

Industry News


From Grifols

New automated diagnostic tests for lupus and ANCA-associated vasculitis, a form of blood vessel inflammation, have been approved by the U.S. Food and Drug Administration. [ read more ]

From Novartis

Novartis's Gilenya (fingolimod) has been approved by the U.S. Food and Drug Administration (FDA) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. Gilenya is the first FDA approval of a drug to treat MS in pediatric patients.  [ read more ]

From Octapharma USA

For the second consecutive year, Octapharma USA will serve as the exclusive sponsor of the nation's only National Camp Exchange for the bleeding disorders community, an adjunct program of the North American Camping Conference of Hemophilia Organizations. [ read more ]

IVIG & Albumin Supply Index


NEW Issue of Biosupply Trends Quarterly!

Current Issue of BSTQ

In this Issue

•  Banishing Burnout in the Healthcare Setting
•  The Evolution of Medical Aid in Dying
•  Are Drugs Really Overpriced?
•  Healthcare Data: Ensuring Regulatory Compliance
•  Myths and Facts: Cataracts

MyFluVaccine Loyalty Program

Want priority access on flu vaccines
for the 2019-2020 season?

Then take advantage of our NEW inclusive MFV Loyalty Program and enroll for the 2019-2020 season when you go to book your flu vaccine orders for the 2018-2019 season through MyFluVaccine.com

  • Priority access on advance released flu vaccines
  • No minimum purchase
  • Hassle-free
  • Guaranteed booking for the products you need

What's New at FFF


CROFAB Crotalidae Polyvalent Immune Fab (Ovine) is indicated for the management of adult and pediatric patients with North American crotalid (Crotalinae subfamily of venomous snakes that includes rattlesnakes, copperheads and cottonmouths/water moccasins) envenomation. It is supplied as a lyophilized powder in vials that contain up to 1 gram of total protein, a maximum of 0.03 mg of mercury, and not less than the indicated number of mouse LD neutralizing units.

For more information about CROFAB, login to biosupply.fffenterprises.com


HYPERRAB is a human rabies immune globulin (RIG) indicated for postexposure prophylaxis, along with rabies vaccine, for persons suspected of exposure to rabies. The new formulation, approved by the U.S. Food and Drug Administration in April, is twice the potency (300 IU/mL) of currently available RIG options, offering a greater concentration of anti-rabies virus antibodies within each mL of volume, meaning fewer injections for patients. It is available in two vial sizes: 1 mL/300 IU and 5 mL/1500 IU. And, although the new RIG is an advancement in patient care, the cost of treatment remains the same as the original product.

For more information about HYPERRAB, login to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective Apr. 1, 2018, through Jun. 30, 2018.

Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
Carimune NF J1566 $71.06 $69.92
Flebogamma J1572 $70.29 $69.16
Gammagard S/D J1566 $71.06 $69.92
Gammaplex J1557 $78.19 $76.93
Octagam J1568 $82.81 $81.49
Privigen J1459 $79.30 $78.03
CUVITRU J1555 $135.25 $133.08
Hizentra J1559 $98.33 $96.75
HyQvia J1575 $138.59 $136.37
Gammagard Liquid J1569 $79.38 $78.10
Gammaked J1561 $78.29 $77.03
Gamunex-C J1561 $78.29 $77.03

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.



FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2018 FFF Enterprises, Inc.